[
  {
    "ts": "2026-01-29T02:05:00+00:00",
    "headline": "This Stock Is Already Up 58% This Year. Is It a Buy?",
    "summary": "This forgotten pandemic stock hasn't said its last word.",
    "url": "https://www.fool.com/investing/2026/01/28/stock-is-already-up-36-this-year-is-it-buy-mrna/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "bd72d658-d7cc-34b0-b739-f9b5b9b09072",
      "content": {
        "id": "bd72d658-d7cc-34b0-b739-f9b5b9b09072",
        "contentType": "STORY",
        "title": "This Stock Is Already Up 58% This Year. Is It a Buy?",
        "description": "",
        "summary": "This forgotten pandemic stock hasn't said its last word.",
        "pubDate": "2026-01-29T02:05:00Z",
        "displayTime": "2026-01-29T02:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/873aca88c51379482f19e9990a2b73a3",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A scientist altering DNA.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fAG8.DNhXAMAkay62WFTdQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/873aca88c51379482f19e9990a2b73a3.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mdqtpb5dvcMZVxO0lHB8rg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/873aca88c51379482f19e9990a2b73a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/28/stock-is-already-up-36-this-year-is-it-buy-mrna/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-already-58-buy-020500857.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T20:09:40+00:00",
    "headline": "Jim Cramer on Moderna: “We Have to Wait and See”",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a cancer vaccination, a caller asked if they should invest in the stock. Cramer replied: Well, I gotta tell you, this is something that they did promise a long time ago, and I hope […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-moderna-wait-see-200940065.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "311e5fcb-422a-33b3-92d2-8fb613885712",
      "content": {
        "id": "311e5fcb-422a-33b3-92d2-8fb613885712",
        "contentType": "STORY",
        "title": "Jim Cramer on Moderna: “We Have to Wait and See”",
        "description": "",
        "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a cancer vaccination, a caller asked if they should invest in the stock. Cramer replied: Well, I gotta tell you, this is something that they did promise a long time ago, and I hope […]",
        "pubDate": "2026-01-29T20:09:40Z",
        "displayTime": "2026-01-29T20:09:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8249220b1710e407dbf8958264db8280",
          "originalWidth": 1920,
          "originalHeight": 1280,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lxe2r2n2Nijz2mfCCmT.Ww--~B/aD0xMjgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/8249220b1710e407dbf8958264db8280.cf.webp",
              "width": 1920,
              "height": 1280,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0gBapk1Nw.YlUdmA3ihFIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8249220b1710e407dbf8958264db8280.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-moderna-wait-see-200940065.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-moderna-wait-see-200940065.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T20:08:21+00:00",
    "headline": "Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance",
    "summary": "Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and co-develop late-stage experimental vaccines, including programs for Epstein Barr virus and herpes simplex virus. This adjustment marks a change in how Moderna plans to advance its mRNA pipeline and share risk on large, expensive studies. Moderna is best known for its mRNA based vaccines, and it...",
    "url": "https://finance.yahoo.com/news/moderna-rethinks-stage-vaccine-funding-200821870.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "427436ee-ff2e-3201-b354-2cdf0de710bc",
      "content": {
        "id": "427436ee-ff2e-3201-b354-2cdf0de710bc",
        "contentType": "STORY",
        "title": "Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance",
        "description": "",
        "summary": "Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and co-develop late-stage experimental vaccines, including programs for Epstein Barr virus and herpes simplex virus. This adjustment marks a change in how Moderna plans to advance its mRNA pipeline and share risk on large, expensive studies. Moderna is best known for its mRNA based vaccines, and it...",
        "pubDate": "2026-01-29T20:08:21Z",
        "displayTime": "2026-01-29T20:08:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-rethinks-stage-vaccine-funding-200821870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-rethinks-stage-vaccine-funding-200821870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]